| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.4K | 1.6% |
| Total Income | 1.4K | 1.6% |
| Expenditure | 1.1K | 5.4% |
| PBT | 299.30 | 16.6% |
| Net Profit | 204.69 | 25.2% |
| OPM | 8.79% | 1.88pp |
| NPM | 14.19% | 3.03pp |
| EPS | 12.42 | 25.1% |
Gland Pharma Reports Q3 FY25 Financial Performance: Revenue of ¥13,841 Mn with Improved Profitability
03 Feb 2025 · 3 Feb 2025, 11:04 pm
Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the third quarter (Q3FY25) ended on December 31st, 2024. The company's revenue was at ¥13,841 Mn with an EBITDA of ¥ 3,600 Mn, resulting in a 26% EBITDA margin. The base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%.
Key Highlights
- 1
Revenue of ¥13,841 Mn with improved profitability
- 2
26% EBITDA margin
- 3
500 basis points improvement in base business EBITDA margin
- 4
Progress in strategic biologics CDMO collaborations
- 5
Successful closure of recent USFDA inspections
Management Comments
Mr. Srinivas Sadu
Executive Chairman of Gland Pharma
Our Q3 FY25 revenue was at € 13,841 Mn. with an EBITDA of € 3,600 Mn., resulting in a 26% EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%.
Mr. Shyamakant Giri
Chief Executive Officer of Gland Pharma
I am honoured and excited to lead Gland Pharma as its new CEO. Building on the company's strong foundation, my focus will be on enhancing operational excellence in our base business, ensuring Cenexi's successful turnaround, identifying and pursuing new growth opportunities, and further solidifying our position as a leader in the CDMO space, particularly in biologics and complex injectables.
Informational and educational content only. Not investment advice.